A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)

Yutaka Imai, Keishi Abe, Yoichi Otsuka, Yutaka Sakurai, Kaoru Yoshinaga

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.

Original languageEnglish
Pages (from-to)311-312
Number of pages2
Journalthe tohoku journal of experimental medicine
Volume131
Issue number3
DOIs
Publication statusPublished - 1980 Jan 1

Keywords

  • Captopril
  • renin
  • renovascular hypertension
  • screening test

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)'. Together they form a unique fingerprint.

  • Cite this